Biodefense Market Report 2026

Biodefense Market Overview

• Biodefense market size has reached to $20.23 billion in 2025 • Expected to grow to $30.05 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: Impact Of Emerging Infectious Diseases Enhanced Biodefense Market • Market Trend: Rapid Advancements In Biodefense Technologies And Products • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biodefense Market?

Biodefense refers to the measures and strategies implemented to protect against biological threats, including the deliberate release of pathogens or biotoxins. This involves the development of detection systems, vaccines, treatments, and emergency response plans to mitigate the impact of biological attacks on public health and safety. Biodefense also includes research and policy efforts to prevent the misuse of biological agents. The main types of biodefense are anthrax, smallpox, botulism, radiation or nuclear, and others. Anthrax refers to a serious infectious disease caused by the bacterium Bacillus anthracis, affecting both humans and animals. It can be contracted through skin contact, inhalation, or ingestion of spores. Biothreat detection devices, including samplers, detectors or triggering devices, identifiers, assays, and others, are used in applications such as hospitals and clinics, ambulatory care centers, and others.

What Is The Biodefense Market Growth Forecast?

The biodefense market size is expected to see strong growth in the next few years. It will grow to $30.05 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to increasing geopolitical instability risks, expansion of global disease monitoring networks, rising investments in next-generation vaccines, growing adoption of ai-driven threat analytics, increasing focus on rapid response biodefense systems. Major trends in the forecast period include increasing deployment of rapid biothreat detection systems, rising development of advanced medical countermeasures, growing investment in pandemic preparedness infrastructure, expansion of integrated emergency response platforms, enhanced focus on biothreat surveillance networks.

Global Biodefense Market Segmentation

1) By Type: Anthrax, Smallpox, Botulism, Other Types 2) By Biothreat Detection Device: Samplers, Detectors Or Triggering Devices, Identifiers, Assays, Other Biothreat Detection Devices 3) By Application: Hospitals And Clinics, Ambulatory Care Centers, Other Applications Subsegments: 1) By Anthrax: Bacillus Anthracis Vaccine, Anthrax Therapeutics 2) By Smallpox: Smallpox Vaccine, Antiviral Drugs For Smallpox 3) By Botulism: Botulism Antitoxin, Botulism Vaccine, Botulinum Neurotoxin Inhibitors 4) By Other Types: Ricin, Plague, Tularemia, Viral Hemorrhagic Fevers

What Is The Driver Of The Biodefense Market?

The recurring threat of emerging infectious diseases is expected to propel the growth of the biodefense market going forward. Infectious diseases refer to illnesses caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi that can spread directly or indirectly from one person to another. The reoccurrence of the threat of emerging infectious diseases highlights the growing challenges posed by pathogens, rapid response, global coordination, and preparedness in biodefense. Biodefense plays a crucial role in infectious disease management by enhancing preparedness, early detection, and rapid response to biological threats, thereby minimizing the impact of outbreaks on public health. For instance, in July 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, in 2023, responded to 72 health emergencies, including 19 “grade-3” high-threat outbreaks, underscoring a sustained spike in emerging infectious diseases year-over-year. Therefore, the reoccurring threat of infectious diseases is driving the growth of the biodefense industry.

Key Players In The Global Biodefense Market

Major companies operating in the biodefense market are Pfizer Inc., Johnson & Johnson, Merck & Co., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca Plc, GSK plc, Gilead Sciences Inc, Novavax Inc, Ichor Medical Systems, Emergent BioSolutions Inc., Alnylam Pharmaceuticals Inc., Dynavax Technologies, Bavarian Nordic, Siga Technologies Inc., Elusys Therapeutics Inc., Ology Bioservices, Altimmune Inc., Hytest Limited, XOMA Corporation, Cleveland BioLabs Inc., Inovio Pharmaceuticals Inc, Dynport Vaccine Company, ViralClear Pharmaceuticals

Global Biodefense Market Trends and Insights

Major companies operating in the biodefense market are focused on developing innovative solutions, such as nasal COVID-19 vaccines, to enhance global preparedness against biological threats. Nasal vaccines enhance biodefense by offering easier administration, potential for mucosal immunity, reduced reliance on needles, enhanced accessibility, and potentially improved immune response. For instance, in January 2023, Bharat Biotech International Limited, an India-based biotechnology company, launched the iNCOVACC Nasal COVID-19 vaccine, utilizing a recombinant replication-deficient adenovirus vector and featuring a pre-fusion stabilized spike protein. After undergoing successful phase I, II, and III clinical trials, this vaccine is designed for intranasal delivery via nasal drops. It is administered as a nasal drop, with a total of 8 drops (0.5 mL per dose), 4 drops into each nostril, as a 2-dose series given 4 weeks apart.

What Are Latest Mergers And Acquisitions In The Biodefense Market?

In September 2023, the Coalition for Epidemic Preparedness Innovations (CEPI), a Norway-based nonprofit focused on accelerating vaccine development and epidemic preparedness, partnered with Bio Farma to boost rapid manufacturing of outbreak vaccines at Indonesia's leading vaccine. With this collaboration, CEPI aims to establish mRNA and viral-vector “rapid-response” vaccine production capacity at Bio Farma, enabling faster manufacturing of outbreak vaccines and reserving production capacity for Global South countries during future epidemics. Bio Farma is an Indonesia-based state-owned company that produces a broad portfolio of WHO-prequalified vaccines and will leverage CEPI’s support to build GMP-standard facilities and bioprocess laboratories for advanced platform technologies.

Regional Outlook

North America was the largest region in the biodefense market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Biodefense Market?

The biodefense market consists of revenues earned by entities by providing services such as threat assessment, surveillance, training, consultation, strategy development, emergency planning, and facility management. The market value includes the value of related goods sold by the service provider or included within the service offering. The biodefense market also includes sales of detection equipment, personal protective gear, vaccines and pharmaceuticals, biological agent identification kits, biocontainment equipment, emergency response kits, biosecurity systems, and communication systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biodefense Market Report 2026?

The biodefense market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biodefense industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.